Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Breast cancer entities : Gilead sciences, inc. save search
Everest Medicines Announces Approval of Trodelvy® in China for Second-Line Metastatic Triple-Negative Breast Cancer
Published: 2022-06-10 (Crawled : 04:00) - prnewswire.com
GILD | $67.08 0.08% 0.06% 6.2M
|
Health Technology
|
| O: -2.99%
H: 0.0%
C: 0.0%
trodelvy approval china cancer breast cancer
Everest Medicines' Licensing Partner Gilead Sciences Announces Positive Results from Phase 3 TROPiCS-02 Study of Trodelvy® in Heavily Pre-treated HR+/HER2- Metastatic Breast Cancer Patients
Published: 2022-06-04 (Crawled : 16:20) - prnewswire.com
GILD | $67.08 0.08% 0.06% 6.2M
|
Health Technology
| Email alert
Add to watchlist
cs-02 trodelvy sciences positive results cancer breast cancer phase 3 her2- her2 metastatic breast cancer
Everest Medicines Submits New Drug Application in Hong Kong for Sacituzumab Govitecan in Second-Line Metastatic Triple-Negative Breast Cancer
Published: 2022-03-30 (Crawled : 01:00) - biospace.com/
GILD | $67.08 0.08% 0.06% 6.2M
|
Health Technology
|
| O: -0.18%
H: 0.53%
C: -1.26%
drug application cancer breast cancer
Everest Medicines Submits New Drug Application in Hong Kong for Sacituzumab Govitecan in Second-Line Metastatic Triple-Negative Breast Cancer
Published: 2022-03-31 (Crawled : 01:00) - prnewswire.com
GILD | $67.08 0.08% 0.06% 6.2M
|
Health Technology
|
| O: 0.52%
H: 0.08%
C: -0.87%
drug application cancer breast cancer
Phase 3 TROPiCS-02 Study Met the Primary Endpoint of Progression-Free Survival in Late-Line HR+/HER2- Metastatic Breast Cancer
Published: 2022-03-07 (Crawled : 14:00) - biospace.com/
GILD | $67.08 0.08% 0.06% 6.2M
|
Health Technology
|
| O: -2.66%
H: 0.0%
C: 0.0%
cs-02 cancer phase 3 breast cancer her2- her2 metastatic breast cancer
Everest Medicines Announces First Drug Approval of Trodelvy® in Singapore for Second-Line Metastatic Triple-Negative Breast Cancer
Published: 2022-02-07 (Crawled : 01:00) - prnewswire.com
GILD | $67.08 0.08% 0.06% 6.2M
|
Health Technology
|
| O: -1.42%
H: 0.0%
C: 0.0%
trodelvy drug approval cancer negative breast cancer
Everest Medicines Announces Taiwan FDA Has Accepted New Drug Application for Sacituzumab Govitecan in Second-Line Metastatic Triple-Negative Breast Cancer
Published: 2022-01-04 (Crawled : 01:00) - prnewswire.com
GILD | $67.08 0.08% 0.06% 6.2M
|
Health Technology
|
| O: 0.4%
H: 0.0%
C: 0.0%
new drug fda application drug cancer negative breast cancer
Everest Medicines Announces the Acceptance of a New Drug Application for Sacituzumab Govitecan in Second-Line Metastatic Triple-Negative Breast Cancer in South Korea
Published: 2021-12-14 (Crawled : 01:00) - biospace.com/
GILD | $67.08 0.08% 0.06% 6.2M
|
Health Technology
|
| O: -0.37%
H: 0.0%
C: 0.0%
new drug application drug cancer negative breast cancer
Everest Medicines Announces the Acceptance of a New Drug Application for Sacituzumab Govitecan in Second-Line Metastatic Triple-Negative Breast Cancer in South Korea
Published: 2021-12-15 (Crawled : 01:00) - prnewswire.com
GILD | $67.08 0.08% 0.06% 6.2M
|
Health Technology
|
| O: 0.99%
H: 1.23%
C: 0.94%
new drug application drug cancer negative breast cancer
Trodelvy® Demonstrates Clinical Benefit for Black Patients Consistent with Full Metastatic Triple-Negative Breast Cancer Population in ASCENT Study
Published: 2021-12-10 (Crawled : 15:00) - biospace.com/
GILD | $67.08 0.08% 0.06% 6.2M
|
Health Technology
|
| O: -0.17%
H: 0.0%
C: 0.0%
trodelvy cancer negative breast cancer
Gilead’s Bold Ambition of Transforming Triple-Negative Breast Cancer Treatment to Be Highlighted With New Data at SABCS
Published: 2021-11-29 (Crawled : 16:00) - biospace.com/
GILD | $67.08 0.08% 0.06% 6.2M
|
Health Technology
|
| O: 0.74%
H: 0.0%
C: 0.0%
treatment cancer negative breast cancer
Everest Medicines and Gilead Sciences Jointly Announce Phase 2b Study of Sacituzumab Govitecan Conducted in China of Patients With Metastatic Triple-negative Breast Cancer Meets Primary Overall Response Rate Endpoint
Published: 2021-11-11 (Crawled : 01:00) - prnewswire.com
GILD | $67.08 0.08% 0.06% 6.2M
|
Health Technology
|
| O: 0.8%
H: 0.73%
C: 0.64%
phase 2 china cancer phase 2b breast cancer
Gilead Announces Clinical Trial Collaboration With Merck to Evaluate Trodelvy® (sacituzumab govitecan-hziy) in Combination With KEYTRUDA® (pembrolizumab) in Patients With First-Line Metastatic Triple-Negative Breast Cancer
Published: 2021-10-28 (Crawled : 22:00) - biospace.com/
GILD | $67.08 0.08% 0.06% 6.2M
|
Health Technology
|
| O: -0.1%
H: 1.44%
C: 0.96%
collaboration cancer breast cancer trial keytruda
Sacituzumab Govitecan Receives Positive CHMP Opinion as 2L Treatment for Adult Patients With Metastatic Triple-Negative Breast Cancer
Published: 2021-10-15 (Crawled : 14:00) - biospace.com/
GILD | $67.08 0.08% 0.06% 6.2M
|
Health Technology
|
| O: 0.9%
H: 0.0%
C: 0.0%
treatment positive cancer chmp breast cancer als
Susan G. Komen® Announces $1.5 Million in Grants for Metastatic Breast Cancer Research
Published: 2021-10-13 (Crawled : 13:00) - biospace.com/
GILD | $67.08 0.08% 0.06% 6.2M
|
Health Technology
|
| O: 0.31%
H: 0.56%
C: 0.07%
cancer research breast cancer granted grant metastatic breast cancer
Trodelvy® Significantly Improved Quality of Life Over Standard of Care in 2L+ Metastatic Triple-Negative Breast Cancer in Phase 3 ASCENT Study
Published: 2021-09-16 (Crawled : 11:33) - biospace.com/
GILD | $67.08 0.08% 0.06% 6.2M
|
Health Technology
|
| O: 0.06%
H: 0.08%
C: -0.65%
cancer phase 3 breast cancer als
New Data Demonstrate Trodelvy® Survival Benefit in Metastatic Triple-Negative Breast Cancer Patients Regardless of Initial HR/HER2 Status
Published: 2021-09-16 (Crawled : 11:33) - biospace.com/
GILD | $67.08 0.08% 0.06% 6.2M
|
Health Technology
|
| O: 0.06%
H: 0.08%
C: -0.65%
cancer breast cancer her2+ her2- her2
Everest Medicines Receives Pediatric and Rare Severe Disease Priority Review Designation from Taiwan FDA for Sacituzumab Govitecan-Hziy in Metastatic Triple-Negative Breast Cancer
Published: 2021-07-29 (Crawled : 11:00) - prnewswire.com
GILD | $67.08 0.08% 0.06% 6.2M
|
Health Technology
|
| O: 0.27%
H: 0.21%
C: -0.6%
disease fda cancer breast cancer designation rare
Everest Medicines Announces China NMPA Has Granted Priority Review for Sacituzumab Govitecan-hziy in Metastatic Triple-Negative Breast Cancer
Published: 2021-05-20 (Crawled : 11:00) - biospace.com/
GILD | $67.08 0.08% 0.06% 6.2M
|
Health Technology
|
| O: 0.23%
H: 1.92%
C: 1.0%
china cancer breast cancer granted grant
Everest Medicines Announces China NMPA Has Accepted Biologics License Application for Sacituzumab Govitecan-Hziy in Metastatic Triple-Negative Breast Cancer
Published: 2021-05-17 (Crawled : 09:00) - prnewswire.com
GILD | $67.08 0.08% 0.06% 6.2M
|
Health Technology
|
| O: -0.07%
H: 1.71%
C: 0.86%
china cancer license breast cancer application
Gainers vs Losers
| 61% | 39% |
Top 10 Gainers
CSSE 4 | $0.4253 179.25% 64.77% 210M
|
Consumer Services
BOF | $2.08 77.78% 41.21% 110M
|
ILAG | $0.54 12.27% 40.62% 3.7M
|
LICN | $0.999 78.39% 40.49% 15M
|
AMST | $3.4 70.0% 39.58% 70M
|
Technology Services
MTC | $3.6 60.71% 38.04% 9.1M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.458 14.5% 30.92% 91K
|
Health Services
WHLM | $6.25 35.87% 28.46% 700K
|
Commercial Services
MULN | News | $3.77 38.1% 27.78% 13M
|
Information
Your saved searches
Save your searches and get alerts when important news are released.